-- European Partnership with Recordati Established to Maximize VAZKEPA in Europe; Global Corporate Restructuring Implemented with Anticipated $70 Million in Operating Expense Savings Over Next 12 Months -- -- Q2 2025 Financial Performance Reflects Incremental Progress for VASCEPA/VAZKEPA in Ex-U.S. Markets, and Continued Stability in U.S. Market -- -- Cash Position Sufficient to Fund Company's Future Growth Path -- DUBLIN and BRIDGEWATER, N.J., July 30, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDA ...